Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 40 | 2025 | 1208 | 10.380 |
Why?
|
| Primary Health Care | 20 | 2024 | 362 | 5.680 |
Why?
|
| Diabetes Mellitus | 20 | 2025 | 758 | 4.190 |
Why?
|
| Hypoglycemic Agents | 16 | 2025 | 361 | 3.640 |
Why?
|
| Psychiatry | 4 | 2023 | 84 | 2.940 |
Why?
|
| Blood Glucose | 14 | 2024 | 855 | 2.780 |
Why?
|
| Depression | 9 | 2024 | 526 | 2.460 |
Why?
|
| Diabetes Complications | 12 | 2024 | 173 | 2.250 |
Why?
|
| Physicians | 7 | 2022 | 693 | 2.120 |
Why?
|
| Mass Screening | 7 | 2024 | 675 | 2.030 |
Why?
|
| Aging | 11 | 2025 | 742 | 1.770 |
Why?
|
| Patient Portals | 2 | 2024 | 18 | 1.670 |
Why?
|
| Qualitative Research | 3 | 2024 | 325 | 1.660 |
Why?
|
| Humans | 108 | 2025 | 92337 | 1.620 |
Why?
|
| Medicaid | 7 | 2022 | 248 | 1.520 |
Why?
|
| Mental Health Services | 3 | 2024 | 62 | 1.440 |
Why?
|
| Cost Sharing | 4 | 2024 | 17 | 1.380 |
Why?
|
| United States | 28 | 2025 | 7366 | 1.360 |
Why?
|
| Hypothyroidism | 5 | 2024 | 263 | 1.330 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2024 | 60 | 1.310 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 739 | 1.190 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 557 | 1.120 |
Why?
|
| Nutrition Surveys | 7 | 2023 | 114 | 1.110 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 3 | 2023 | 39 | 1.110 |
Why?
|
| Healthcare Disparities | 4 | 2022 | 443 | 1.080 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 64 | 1.060 |
Why?
|
| Documentation | 3 | 2022 | 103 | 1.060 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 171 | 1.050 |
Why?
|
| Physicians, Primary Care | 2 | 2020 | 104 | 1.010 |
Why?
|
| Interviews as Topic | 3 | 2024 | 351 | 0.960 |
Why?
|
| Adult | 30 | 2025 | 27545 | 0.940 |
Why?
|
| Female | 51 | 2025 | 47897 | 0.930 |
Why?
|
| Aged | 39 | 2025 | 19947 | 0.930 |
Why?
|
| Male | 49 | 2025 | 43919 | 0.920 |
Why?
|
| Cross-Sectional Studies | 16 | 2024 | 1771 | 0.900 |
Why?
|
| Middle Aged | 35 | 2025 | 27045 | 0.850 |
Why?
|
| Cost-Benefit Analysis | 10 | 2025 | 488 | 0.850 |
Why?
|
| Chronic Disease | 4 | 2022 | 966 | 0.820 |
Why?
|
| Hormone Replacement Therapy | 3 | 2024 | 92 | 0.810 |
Why?
|
| Health Expenditures | 1 | 2024 | 97 | 0.800 |
Why?
|
| Quality-Adjusted Life Years | 8 | 2025 | 153 | 0.780 |
Why?
|
| Anxiety | 2 | 2024 | 324 | 0.780 |
Why?
|
| Insurance | 1 | 2022 | 12 | 0.770 |
Why?
|
| Population Health | 1 | 2022 | 33 | 0.770 |
Why?
|
| Hyperthyroidism | 1 | 2022 | 76 | 0.750 |
Why?
|
| Metformin | 2 | 2024 | 132 | 0.740 |
Why?
|
| Systems Integration | 2 | 2021 | 35 | 0.740 |
Why?
|
| Outpatients | 1 | 2022 | 106 | 0.740 |
Why?
|
| Schools, Medical | 1 | 2023 | 137 | 0.730 |
Why?
|
| Hospitalization | 3 | 2021 | 925 | 0.720 |
Why?
|
| Health Services Accessibility | 4 | 2021 | 452 | 0.720 |
Why?
|
| Referral and Consultation | 1 | 2024 | 353 | 0.710 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 236 | 0.710 |
Why?
|
| Obesity | 4 | 2025 | 1006 | 0.710 |
Why?
|
| Quality of Life | 7 | 2021 | 1745 | 0.700 |
Why?
|
| Patient Preference | 2 | 2025 | 120 | 0.680 |
Why?
|
| Thyroid Hormones | 2 | 2023 | 349 | 0.680 |
Why?
|
| Financing, Organized | 1 | 2020 | 13 | 0.670 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 24 | 0.660 |
Why?
|
| Breast Density | 1 | 2020 | 35 | 0.650 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 232 | 0.640 |
Why?
|
| State Health Plans | 1 | 2019 | 13 | 0.630 |
Why?
|
| Program Evaluation | 1 | 2020 | 316 | 0.610 |
Why?
|
| Hypertension | 3 | 2016 | 763 | 0.600 |
Why?
|
| Quality of Health Care | 3 | 2022 | 390 | 0.590 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 378 | 0.590 |
Why?
|
| Early Medical Intervention | 1 | 2018 | 19 | 0.590 |
Why?
|
| Veterans | 1 | 2019 | 89 | 0.580 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 290 | 0.570 |
Why?
|
| Medicare | 4 | 2024 | 440 | 0.570 |
Why?
|
| Community Health Centers | 2 | 2022 | 116 | 0.570 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2024 | 574 | 0.540 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 437 | 0.530 |
Why?
|
| Public Health | 2 | 2021 | 146 | 0.520 |
Why?
|
| Health Policy | 2 | 2016 | 190 | 0.510 |
Why?
|
| Risk Assessment | 6 | 2025 | 2368 | 0.510 |
Why?
|
| Quality Improvement | 2 | 2017 | 474 | 0.510 |
Why?
|
| Communication | 1 | 2020 | 462 | 0.510 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2016 | 4 | 0.500 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 334 | 0.500 |
Why?
|
| Thyroxine | 5 | 2024 | 376 | 0.490 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 424 | 0.490 |
Why?
|
| Surveys and Questionnaires | 10 | 2025 | 2730 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 315 | 0.480 |
Why?
|
| Thyrotropin | 4 | 2024 | 302 | 0.470 |
Why?
|
| Attitude to Health | 1 | 2016 | 221 | 0.470 |
Why?
|
| HIV Infections | 1 | 2024 | 896 | 0.460 |
Why?
|
| Glucose | 3 | 2022 | 682 | 0.460 |
Why?
|
| Medication Adherence | 1 | 2016 | 147 | 0.460 |
Why?
|
| Insurance Coverage | 2 | 2019 | 134 | 0.450 |
Why?
|
| Opioid-Related Disorders | 3 | 2022 | 202 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1075 | 0.430 |
Why?
|
| Leadership | 2 | 2017 | 147 | 0.430 |
Why?
|
| Preventive Health Services | 1 | 2014 | 39 | 0.430 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 3775 | 0.430 |
Why?
|
| Health Care Reform | 2 | 2015 | 85 | 0.420 |
Why?
|
| Coronary Disease | 1 | 2014 | 262 | 0.390 |
Why?
|
| Bariatric Surgery | 2 | 2017 | 203 | 0.390 |
Why?
|
| Disease Progression | 4 | 2024 | 1500 | 0.380 |
Why?
|
| Comorbidity | 5 | 2018 | 986 | 0.370 |
Why?
|
| Young Adult | 8 | 2025 | 6622 | 0.350 |
Why?
|
| Sodium | 2 | 2022 | 335 | 0.350 |
Why?
|
| Models, Economic | 3 | 2024 | 62 | 0.350 |
Why?
|
| Informed Consent | 2 | 2023 | 278 | 0.350 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 115 | 0.340 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 175 | 0.330 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2024 | 55 | 0.320 |
Why?
|
| Risk Factors | 7 | 2025 | 5705 | 0.320 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 226 | 0.310 |
Why?
|
| Insulin | 3 | 2024 | 1165 | 0.300 |
Why?
|
| Markov Chains | 2 | 2020 | 131 | 0.300 |
Why?
|
| Prospective Studies | 7 | 2024 | 4473 | 0.290 |
Why?
|
| Monte Carlo Method | 2 | 2020 | 188 | 0.290 |
Why?
|
| Hypoglycemia | 2 | 2024 | 110 | 0.290 |
Why?
|
| Aged, 80 and over | 11 | 2025 | 6918 | 0.290 |
Why?
|
| Life Expectancy | 3 | 2023 | 89 | 0.280 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 67 | 0.270 |
Why?
|
| California | 5 | 2025 | 156 | 0.260 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2793 | 0.250 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2025 | 56 | 0.250 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 57 | 0.250 |
Why?
|
| Attitude of Health Personnel | 3 | 2022 | 658 | 0.250 |
Why?
|
| Chronic Pain | 2 | 2022 | 171 | 0.240 |
Why?
|
| Medicare Part D | 1 | 2025 | 12 | 0.230 |
Why?
|
| Glucagon-Like Peptides | 1 | 2025 | 12 | 0.230 |
Why?
|
| Job Satisfaction | 2 | 2018 | 80 | 0.230 |
Why?
|
| Anti-Obesity Agents | 1 | 2025 | 15 | 0.230 |
Why?
|
| Deprescriptions | 1 | 2025 | 10 | 0.230 |
Why?
|
| Costs and Cost Analysis | 3 | 2020 | 154 | 0.230 |
Why?
|
| Health Care Surveys | 2 | 2019 | 286 | 0.230 |
Why?
|
| Triiodothyronine | 2 | 2023 | 358 | 0.220 |
Why?
|
| Chicago | 2 | 2024 | 1463 | 0.220 |
Why?
|
| Colorado | 1 | 2024 | 37 | 0.220 |
Why?
|
| Internship and Residency | 2 | 2011 | 1087 | 0.220 |
Why?
|
| Health Care Costs | 3 | 2024 | 247 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2024 | 9694 | 0.220 |
Why?
|
| Self-Management | 1 | 2024 | 43 | 0.220 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 1117 | 0.220 |
Why?
|
| Osteoporotic Fractures | 1 | 2025 | 51 | 0.220 |
Why?
|
| Efficiency | 2 | 2021 | 39 | 0.210 |
Why?
|
| Physician-Patient Relations | 3 | 2016 | 630 | 0.210 |
Why?
|
| Bone Density | 1 | 2025 | 228 | 0.210 |
Why?
|
| Fractures, Bone | 1 | 2025 | 148 | 0.200 |
Why?
|
| Logistic Models | 2 | 2019 | 1239 | 0.200 |
Why?
|
| Urban Population | 1 | 2024 | 228 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 103 | 0.200 |
Why?
|
| Parental Leave | 1 | 2023 | 11 | 0.200 |
Why?
|
| Prevalence | 2 | 2019 | 1297 | 0.200 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 5 | 0.200 |
Why?
|
| Insurance, Health | 2 | 2015 | 172 | 0.200 |
Why?
|
| Faculty | 1 | 2023 | 35 | 0.200 |
Why?
|
| Academic Medical Centers | 3 | 2023 | 399 | 0.190 |
Why?
|
| Analgesics, Opioid | 3 | 2022 | 470 | 0.190 |
Why?
|
| Organizational Policy | 1 | 2023 | 55 | 0.190 |
Why?
|
| Suicide | 1 | 2024 | 151 | 0.190 |
Why?
|
| Antipsychotic Agents | 1 | 2023 | 140 | 0.190 |
Why?
|
| Fee-for-Service Plans | 1 | 2022 | 30 | 0.190 |
Why?
|
| Buprenorphine | 1 | 2022 | 43 | 0.190 |
Why?
|
| Waiting Lists | 1 | 2023 | 200 | 0.180 |
Why?
|
| Adolescent | 4 | 2024 | 9490 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 105 | 0.180 |
Why?
|
| Dementia | 1 | 2023 | 203 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2020 | 901 | 0.160 |
Why?
|
| Computers | 1 | 2020 | 111 | 0.160 |
Why?
|
| Time Factors | 4 | 2021 | 5429 | 0.160 |
Why?
|
| Pandemics | 2 | 2023 | 807 | 0.160 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 43 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 129 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 886 | 0.160 |
Why?
|
| Fasting | 1 | 2020 | 164 | 0.160 |
Why?
|
| Emotions | 1 | 2023 | 365 | 0.160 |
Why?
|
| Hospitals | 1 | 2022 | 313 | 0.160 |
Why?
|
| Blood Pressure | 2 | 2015 | 906 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 116 | 0.150 |
Why?
|
| Demography | 2 | 2023 | 186 | 0.150 |
Why?
|
| Internal Medicine | 4 | 2021 | 366 | 0.150 |
Why?
|
| Length of Stay | 1 | 2022 | 790 | 0.150 |
Why?
|
| United Kingdom | 2 | 2024 | 173 | 0.140 |
Why?
|
| Electronic Health Records | 2 | 2021 | 364 | 0.140 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 20 | 0.140 |
Why?
|
| Work Engagement | 1 | 2017 | 6 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2023 | 2979 | 0.140 |
Why?
|
| Health Status Disparities | 2 | 2023 | 200 | 0.140 |
Why?
|
| Inservice Training | 1 | 2017 | 38 | 0.140 |
Why?
|
| Poverty | 1 | 2019 | 189 | 0.140 |
Why?
|
| Patient Participation | 1 | 2019 | 227 | 0.140 |
Why?
|
| Urban Health Services | 1 | 2017 | 44 | 0.140 |
Why?
|
| Cost Savings | 1 | 2017 | 71 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 353 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 498 | 0.130 |
Why?
|
| Diet Therapy | 1 | 2016 | 19 | 0.130 |
Why?
|
| Financing, Personal | 1 | 2016 | 21 | 0.130 |
Why?
|
| Perception | 1 | 2017 | 183 | 0.130 |
Why?
|
| Linear Models | 2 | 2018 | 427 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2016 | 88 | 0.120 |
Why?
|
| Safety-net Providers | 1 | 2016 | 43 | 0.120 |
Why?
|
| Overweight | 1 | 2017 | 120 | 0.120 |
Why?
|
| Sexual and Gender Minorities | 1 | 2019 | 230 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 116 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 808 | 0.120 |
Why?
|
| Medical Overuse | 1 | 2016 | 36 | 0.120 |
Why?
|
| Life Style | 1 | 2016 | 176 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1920 | 0.120 |
Why?
|
| Phenotype | 1 | 2021 | 2503 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2018 | 1512 | 0.110 |
Why?
|
| Data Accuracy | 1 | 2015 | 32 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 505 | 0.110 |
Why?
|
| Federal Government | 1 | 2014 | 29 | 0.110 |
Why?
|
| Health Surveys | 2 | 2013 | 242 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 234 | 0.110 |
Why?
|
| Medically Uninsured | 1 | 2014 | 64 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2018 | 1112 | 0.100 |
Why?
|
| Primary Prevention | 2 | 2013 | 82 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 237 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 2015 | 331 | 0.100 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 10 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 359 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2014 | 694 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2017 | 798 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 279 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2022 | 8729 | 0.090 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 66 | 0.090 |
Why?
|
| Registries | 2 | 2013 | 903 | 0.090 |
Why?
|
| Medical Audit | 1 | 2011 | 39 | 0.090 |
Why?
|
| Burnout, Professional | 1 | 2013 | 104 | 0.090 |
Why?
|
| Prognosis | 2 | 2016 | 3871 | 0.090 |
Why?
|
| Health Status | 2 | 2023 | 375 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2010 | 172 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 215 | 0.080 |
Why?
|
| Disease Management | 1 | 2011 | 341 | 0.080 |
Why?
|
| Counseling | 1 | 2009 | 171 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2009 | 0.070 |
Why?
|
| Stroke | 1 | 2015 | 1038 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 369 | 0.060 |
Why?
|
| Brazil | 1 | 2024 | 77 | 0.060 |
Why?
|
| Hip Fractures | 1 | 2025 | 50 | 0.060 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 10 | 0.060 |
Why?
|
| Calibration | 1 | 2024 | 103 | 0.060 |
Why?
|
| Drug Costs | 1 | 2025 | 68 | 0.050 |
Why?
|
| Insulin Glargine | 1 | 2023 | 12 | 0.050 |
Why?
|
| Algorithms | 1 | 2011 | 1961 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2023 | 124 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 5 | 0.050 |
Why?
|
| Dronabinol | 1 | 2023 | 58 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 156 | 0.050 |
Why?
|
| Methadone | 1 | 2022 | 48 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2022 | 68 | 0.050 |
Why?
|
| Systems Analysis | 1 | 2021 | 17 | 0.040 |
Why?
|
| Naltrexone | 1 | 2022 | 139 | 0.040 |
Why?
|
| Jurisprudence | 1 | 2021 | 25 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 391 | 0.040 |
Why?
|
| Community Networks | 1 | 2021 | 30 | 0.040 |
Why?
|
| Illinois | 1 | 2021 | 502 | 0.040 |
Why?
|
| Social Stigma | 1 | 2019 | 76 | 0.040 |
Why?
|
| Survival Rate | 2 | 2014 | 1926 | 0.040 |
Why?
|
| Economics, Medical | 1 | 2018 | 6 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 306 | 0.040 |
Why?
|
| Mental Health | 1 | 2019 | 183 | 0.040 |
Why?
|
| Biomarkers | 1 | 2024 | 1847 | 0.040 |
Why?
|
| Checklist | 1 | 2018 | 68 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 617 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 102 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 156 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 28047 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 238 | 0.030 |
Why?
|
| Philippines | 1 | 2015 | 22 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 48 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 52 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 600 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 610 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1733 | 0.030 |
Why?
|
| Clinical Audit | 1 | 2013 | 9 | 0.030 |
Why?
|
| New York City | 1 | 2013 | 60 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 899 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2013 | 85 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 26 | 0.020 |
Why?
|
| Family Practice | 1 | 2013 | 84 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 995 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 173 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 206 | 0.020 |
Why?
|
| Medical Errors | 1 | 2013 | 115 | 0.020 |
Why?
|
| Brain | 1 | 2021 | 2353 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2013 | 239 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1661 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1903 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 379 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2009 | 333 | 0.020 |
Why?
|